Results 141 to 150 of about 1,706,856 (229)

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. [PDF]

open access: yesSupport Care Cancer, 2023
Herrstedt J   +8 more
europepmc   +1 more source

Recapitulating In Vivo Pharmacokinetics and Size‐Dependent Nanomedicine Delivery in a Microfluidic Platform

open access: yesAdvanced Science, EarlyView.
A microfluidic tumor platform integrates pharmacokinetic flow control, vascular‐like barriers, and 3D tumor spheroids to emulate in vivo drug exposure. The system reproduces dynamic concentration–time profiles and enables size‐dependent nanoparticle transport and efficacy evaluation, providing a predictive framework for assessing nanomedicine ...
Su Jeong Kang   +5 more
wiley   +1 more source

Multi‐Omics Integration Identifies a CDH3‐Associated Malignant Epithelial State and Immunosuppressive Niche to Predict Prognosis in Thymic Epithelial Tumors

open access: yesAdvanced Science, EarlyView.
Single‐cell, spatial, molecular, and pathology analyses identify a CDH3‐associated malignant epithelial state in thymic epithelial tumors. This state links stem‐like and EMT programs to M2 macrophage–rich immunosuppressive niches, genomic instability, poor survival, and drug vulnerability.
Yuntao Feng   +13 more
wiley   +1 more source

Pulmonary toxicity from novel antineoplastic agents

open access: yes, 2006
Background: The pulmonary side-effects induced by novel antineoplastic agents have not been well characterized. Methods: To further investigate this topic, relevant English and non-English language studies were identified through Medline.
Bamias, A   +3 more
core  

Safety and efficacy of an outpatient 12-step desensitization protocol for antineoplastic agents. [PDF]

open access: yesInt J Gynecol Cancer, 2022
Eroglu I   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy